HNRNPA2B1 and gastric cancer: Increased TRIM29 is responsible for the stemness and cisplatin resistance to the cancer cells.[53] The m6A reader hnRNPA2B1 is overexpressed in gastric cancer (GC) cells which enhances stemness properties through stabilization of lncRNA NEAT1 and activation of Wnt/β‐catenin pathway, thus conferring resistance to multiple chemotherapeutic agents including Adriamycin (doxorubicin), Vincristine and 5‐FU.[54]